MPL codon 515 Mutation Detection by Pyrosequencing, Quantitative
2005545
Ordering Recommendation
May be useful when suspicion for  myeloproliferative neoplasms (MPN) is high in JAK2 V617F-negative individuals.
Mnemonic
MPL
Methodology
Polymerase Chain Reaction/Quantitative Pyrosequencing
Performed
DNA isolation: Sun-Sat
Assay: Varies
Reported
7-12 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Additional Technical InformationAdditional Technical Information
 
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA).  
Specimen Preparation
Transport 5 mL whole blood or bone marrow. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Plasma or serum. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens.  
Remarks
  
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable  
Reference Interval
   
Interpretive Data
Refer to report

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
The test will detect and quantify MPL codon 515 mutation, including W515K and W515L.
CPT Code(s)
81402
Components
Component Test Code*Component Chart NameLOINC
2005546MPL codon 515 results58009-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • JAK-2 negative MPN diagnosis
  • JAK2 V617 negative testing
  • MPL 1p34